Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Citius Pharmaceuticals Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Citius Pharmaceuticals Inc trades at $0.58 (market cap $16.00M). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 2493.1× Citius Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| ALNY | CTXR | |
|---|---|---|
Market Cap | $39.89B | $16.00M |
Sector | Health | Health |
52-Week High | $491.22 | $1.82 |
52-Week Low | $278.09 | $0.53 |
Enterprise Value | $38.15B | $12.21M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
CTXR trades at $0.5827, up 3.81% today, but technical indicators show a bearish trend with moving averages signaling sell pressure. The company reported a net loss of $37.43M in 2025 with a -823.34% net margin, though revenue reached $5.6M in H1 2026 from LYMPHIR commercialization. Recent news highlights positive Phase 1 data for LYMPHIR presented at ASCO 2026.
Outlook remains speculative with high cash burn offset by financing; analyst consensus is 83% buy but financial sustainability depends on successful drug adoption. Key risks include clinical trial outcomes, dilution from recent $5M offering, and achieving profitability amid ongoing losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
